Entities / Company
Merck.
public company in Indonesia
- Reports this week
- 13
- Active events
- 11
- Connections
- 247
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Moderna and Merck reported a landmark result from their melanoma study, while SanDisk and Dell were discussed in stock market analysis.Well supported3 reports1 development inside
-
Merck is expanding its operations in Montgomery County.Some support1 report
-
Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.Some support2 reports
-
Amgen and Merck are currently competing against each other in the market for investor capital.Some support4 reports
-
Merck is expanding its R&D and manufacturing operations across Kansas, Delaware, Virginia, and Pennsylvania.Some support1 report
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Well supported4 reports2 developments inside
-
Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.Well supported14 reports1 development inside
-
Uğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.Some support1 report
-
A new facility has opened in Sheboygan Falls, strengthening the area's global profile through investment.Some support1 report1 development inside
-
Merck developed the experimental eye treatment remigromig, leading Jefferies to cut sales forecasts due to trial concerns.Some support1 report
-
A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.Some support1 report2 developments inside
Earlier this month
-
Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.Well supported3 reports3 developments inside
-
Seagate Technology, Merck, and Hewlett Packard Enterprise paid quarterly dividends on October 8, 2026.Some support1 report
-
Moderna and Merck conducted a study on mRNA vaccine while Rob Sand campaigned for Iowa governor, proposing plans to tackle cancer.Some support1 report
-
Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Well supported4 reports
-
Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Some support1 report
-
Janus Henderson is backing biotech reverse mergers while dueling drug data emerges between involved companies.Some support2 reports
-
Bank of America led Merck's $5 billion financing deal, alongside bond sales by automakers, amid market anticipation of FED rate decisions.Some support1 report1 development inside
-
Bank of America shared insights from Merck's CMO regarding the ongoing financing deal.Some support1 report
-
Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.Some support1 report
-
Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.Some support2 reports
-
Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.Some support6 reports
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.Some support1 report
-
Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.Some support5 reports
-
Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.Well supported4 reports
-
ISS research contributed to the formulation of Keytruda, a medical application involving Chief Engineer Ariel Ekblaw and Michael Roberts.Some support1 report
-
Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.Some support1 report1 development inside
One to three months ago
-
Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.Some support3 reports4 developments inside
-
Merck's Animal Health segment is performing well, and the company discussed transformation during a meeting with Morgan Stanley.Some support1 report
-
A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.Well supported3 reports
-
Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.Some support3 reports
-
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Well supported18 reports10 developments inside
-
OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.Well supported5 reports
-
Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.Some support3 reports1 development inside
-
Dr. Cannon gained experience at Merck, involving Lindus Therapeutics.Some support1 report
-
Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.Some support2 reports
-
Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.Some support1 report
-
Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.Some support2 reports
-
Merck's stock price increased following positive drug performance involving Summit Therapeutics.Some support1 report
-
Companies including UnitedHealth Group, Procter & Gamble, Abbott Laboratories, and Merck are noted as being included in high-quality dividend ETFs.Some support1 report1 development inside
-
The Schwab U.S. Dividend Equity ETF now includes Procter & Gamble, Abbott Laboratories, and Merck among its top 10 holdings.Some support1 report
-
Moderna and Merck are developing an experimental melanoma vaccine with partners, while concerns about AI models are impacting Gartner's business.Some support2 reports
-
Merck has set the list price for a drug that received approval from the FDA.Some support1 report
-
Moderna combined its vaccine with Merck's Keytruda drug.Some support3 reports
-
Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.Some support2 reports
-
Berkshire Hathaway and Warren Buffett commented on the Moderna and Merck partnership, criticizing market speculation while noting positive news regarding the mRNA vaccine collaboration.Some support1 report
-
Moderna and Merck announced initial results from a late-stage trial for their novel cancer treatment.Some support3 reports
-
Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.Some support1 report
-
Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.Well supported7 reports2 developments inside
-
Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.Some support2 reports
-
Positive Phase 3 data announced from the combined treatment trials involving Moderna and Merck.Well supported3 reports
-
The new event is a composite of two unrelated stories: FED inaction on inflation and successful cancer therapy trial results involving Moderna and Merck.Some support2 reports
-
Positive interim readout reported for melanoma trials involving Moderna and Merck.Well supported4 reports
-
Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.Some support2 reports
-
Moderna and Merck are developing a combination therapy using Keytruda.Well supported7 reports
-
Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.Well supported36 reports2 developments inside
-
Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.Some support3 reports3 developments inside
-
Andrew Wakefield recommended separating shots in 1998, noting that products would take Merck over a decade to develop.Some support1 report
-
Vaccine trial successes boosted Moderna and Merck, while investors awaited Fed minutes amid geopolitical uncertainty in the Middle East and disappointing OpenAI results.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Merck
Events traced to Merck, step by step, newest first- Merck may benefit from defensive capital rotation into healthcareMerck could benefit from defensive capital rotation into healthcare stocksPossible
- Roche's new oncology collaboration may intensify competition for MerckRoche's new oncology collaboration may intensify competition for MerckPossible
- How will the generic ANDA submission for Sitagliptin affect Merck?Generic competitor challenges market exclusivity of Sitagliptin tabletsReported
Around Merck this week
News at the entities that move Merck most-
FDA StructuralFDA-approved products are subject to Controlled Substances Act rules, impacting TerrAscend's operations across Pennsylvania, Maryland, New Jersey, and Ohio.Moves Merck
-
Bank of America OperationalBank of America CEO Brian Moynihan warned of a soft financial quarter for the bank.Moves Merck
-
Health Canada StructuralNeighboring provinces are monitoring Chronic Wasting Disease (CWD) and Health Canada is advising on human risk.Moves Merck
-
Moderna OperationalModerna and BioNTech are recognized as leaders in the personalized cancer vaccine space.Moves Merck
-
Tempus StructuralStudy results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.Moves Merck
-
Pfizer OperationalAbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.Moves Merck
Connections
The 40 strongest of 247, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Moderna Operational
Moderna and Merck are engaged in an ongoing partnership to jointly develop personalized mRNA cancer vaccines and combination therapies.
-
Verona Pharma Structural
Merck acquired Verona Pharma for $10 billion, integrating its pipeline and products into Merck's operations.
-
FDA Structural
The FDA functions as the mandatory regulatory gatekeeper, evaluating and granting market approval for Merck's pharmaceutical products.
-
Azad Bonni Structural
Azad Bonni holds the role of senior vice president at Merck.
-
OGN Structural
OGN is a subsidiary of Merck, having been spun off from the parent company in 2021.
-
MSD Structural
MSD functions as the regional name and subsidiary of Merck outside of the US and Canada.
-
Tempus Structural
Tempus supplies diagnostic data and AI tools and partners with Merck on clinical trials.
-
Verona Structural
Merck acquired Verona, establishing an ownership relationship that integrates Verona's assets into Merck's drug portfolio.
Show all 40 connections
-
Merck Animal Health Structural
Merck Animal Health operates as a formal division of the larger corporate entity, Merck & Co., Inc.
-
Dean Y. Li Structural
Dean Y. Li serves as president of Merck Research Laboratories.
-
AstraZeneca Operational
AstraZeneca and Merck actively compete in the oncology space while simultaneously engaging in strategic partnerships and profit-sharing agreements.
-
Pfizer Operational
Pfizer and Merck are major pharmaceutical companies engaged in direct competition across key markets including oncology, candidemia, and glaucoma.
-
Zoetis Operational
Zoetis and Merck actively compete in the healthcare market, particularly in animal and equine health segments.
-
Bank of America Operational
Bank of America served as the lead financial institution for Merck's $5 billion financing round, establishing a high-stakes operational partnership.
-
Eli Lilly and Company Operational
Eli Lilly and Merck are direct, high-stakes competitors in the pharmaceutical market, particularly in GLP-1 and oncology therapeutics.
-
Amgen Operational
Amgen and Merck are direct competitors in the biosimilar market and compete for investor capital and market growth.
-
Rob Davis Structural
Rob Davis serves as the Chairman and CEO of Merck.
-
Animal Health Structural
Animal Health functions as a specific, integrated business segment within the larger Merck corporate structure.
-
Novartis Operational
The companies are direct competitors in the advanced therapies market and are frequently grouped as top holdings in sector-specific ETFs.
-
OPKO Health (Ireland) Operational
OPKO Health and Merck are actively collaborating on the development and advancement of an Epstein-Barr virus vaccine candidate.
-
Medicare Transactional
Merck engages in specific pricing and access negotiations with Medicare regarding its drugs and services.
-
Gilead Sciences Structural
Gilead relies on Merck's products for combination therapies and the companies are actively partnering on new drug development.
-
Health Canada Structural
Health Canada regulates and approves Merck's pharmaceutical products, enabling their market access in Canada.
-
Narendra Modi Structural
The relationship is defined by the government-led procurement and utilization of Merck's products for the national vaccination campaign.
-
Control Data Corporation Operational
CDC evaluates and recommends Merck's pharmaceutical products, facing current allegations of data falsification.
-
Daiichi Operational
Merck and Daiichi are engaged in a formal co-development partnership for a Phase III clinical study following the acquisition of co-development rights.
-
Vassiliki Karantza Structural
Vassiliki Karantza is employed as an Associate Vice President at Merck.
-
DRC Transactional
Merck provided the Ervebo vaccine for use in a clinical trial conducted in the DRC.
-
CoreWeave Structural
CoreWeave plans to establish its facility on land previously owned by Merck.
-
Rob Davis Structural
Rob Davis serves as the chairman and CEO of Merck.
-
Robert F. Kennedy Jr. Operational
A promotes B's products through recommendations but also targets B through product liability lawsuits.
-
Hyperion Structural
Hyperion's clinical trial data is utilized by Merck in its drug development and evaluation processes.
-
GSK Operational
GSK and Merck are direct competitors in the market due to their production and sale of combination MMR shots.
-
Hoffmann-La Roche Operational
Roche and Merck are direct competitors in the immuno-oncology and PD-L1 inhibitor markets.
-
Ligand Pharmaceuticals Structural
The companies are in a partnership where Merck funds Ligand's drug development and provides royalty revenue from its portfolio.
-
Donald Trump Operational
Trump's political and regulatory actions directly influence Merck's operational decisions, product development, and market strategy.
-
Veeva Systems Operational
Veeva Systems provides software and strategic services to Merck, which commits to implementing these solutions.
-
Cidara Therapeutics Structural
Merck acquired Cidara Therapeutics, establishing a current parent-subsidiary relationship.
-
Johnson & Johnson Operational
Johnson & Johnson and Merck are major pharmaceutical companies actively competing in specialized drug markets like oncology and PAH.
-
Bristol-Myers Squibb Operational
Both companies actively compete in the oncology sector and are frequently included in the SCHD ETF.
History
Events by the month they beganOctober 2026
9 events- Moderna and Merck reported a landmark result from their melanoma study, while SanDisk and Dell were discussed in stock market analysis.
- Merck is expanding its operations in Montgomery County.
- Moderna, Pfizer, and Merck are part of a healthcare rotation story, with Moderna outperforming Pfizer in current stock gains.
- Merck is expanding its R&D and manufacturing operations across Kansas, Delaware, Virginia, and Pennsylvania.
- Uğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.
- A new facility has opened in Sheboygan Falls, strengthening the area's global profile through investment.
- Merck developed the experimental eye treatment remigromig, leading Jefferies to cut sales forecasts due to trial concerns.
- Seagate Technology, Merck, and Hewlett Packard Enterprise paid quarterly dividends on October 8, 2026.
- Moderna and Merck conducted a study on mRNA vaccine while Rob Sand campaigned for Iowa governor, proposing plans to tackle cancer.
September 2026
16 events- Amgen and Merck are currently competing against each other in the market for investor capital.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.
- Janus Henderson is backing biotech reverse mergers while dueling drug data emerges between involved companies.
- Bank of America shared insights from Merck's CMO regarding the ongoing financing deal.
- Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.
- ISS research contributed to the formulation of Keytruda, a medical application involving Chief Engineer Ariel Ekblaw and Michael Roberts.
- Merck's Animal Health segment is performing well, and the company discussed transformation during a meeting with Morgan Stanley.
- Dr. Cannon gained experience at Merck, involving Lindus Therapeutics.
- Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.
- Merck's stock price increased following positive drug performance involving Summit Therapeutics.
- The Schwab U.S. Dividend Equity ETF now includes Procter & Gamble, Abbott Laboratories, and Merck among its top 10 holdings.
- Moderna and Merck are developing an experimental melanoma vaccine with partners, while concerns about AI models are impacting Gartner's business.
August 2026
23 events- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.
- A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.
- Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.
- Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.
- Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.
- Merck has set the list price for a drug that received approval from the FDA.
- Moderna combined its vaccine with Merck's Keytruda drug.
- Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.
- Berkshire Hathaway and Warren Buffett commented on the Moderna and Merck partnership, criticizing market speculation while noting positive news regarding the mRNA vaccine collaboration.
- Moderna and Merck announced initial results from a late-stage trial for their novel cancer treatment.
- Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.
- Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.
- Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.
- Positive Phase 3 data announced from the combined treatment trials involving Moderna and Merck.
- The new event is a composite of two unrelated stories: FED inaction on inflation and successful cancer therapy trial results involving Moderna and Merck.
- Positive interim readout reported for melanoma trials involving Moderna and Merck.
- Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.
- Moderna and Merck are developing a combination therapy using Keytruda.
- Andrew Wakefield recommended separating shots in 1998, noting that products would take Merck over a decade to develop.
- Vaccine trial successes boosted Moderna and Merck, while investors awaited Fed minutes amid geopolitical uncertainty in the Middle East and disappointing OpenAI results.
Show 2 earlier months
July 2026
1 eventJune 2026
11 events- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
- Bank of America led Merck's $5 billion financing deal, alongside bond sales by automakers, amid market anticipation of FED rate decisions.
- Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.
- Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.
- Companies including UnitedHealth Group, Procter & Gamble, Abbott Laboratories, and Merck are noted as being included in high-quality dividend ETFs.
- Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.